Efficacy in Itch Relief

In a sub-analysis of the PSO-FAST study, Enstilar® provided significant and sustained itch relief1

Of 300 patients with VAS score >30, those on Enstilar® experienced a significant itch reduction
from baseline vs foam vehicle by day 3 (P=0.019), with continued improvement
for 4 weeks (P<0.001, each time point).1

Change in itch VAS scores over 4 weeks in plaque psoriasis patients with clinically relevant itch (baseline VAS score >30)1

Enstilar® (calcipotriol / betamethasone dipropionate) itch relief data

*P=0.019, †P<0.001, Enstilar® vs foam vehicle. Bars represent 95% confidence intervals (CI).
Adapted from Stein Gold L et al. EADV 2017.

Study details

PSO-FAST was a randomised, double-blind, vehicle-controlled, 4-week Phase III trial conducted in 426 patients with mild to severe plaque psoriasis. Patients included in this sub-analysis were those with a baseline itch VAS score >30, i.e., of clinical relevance,also described as itch that is at least moderate.Assessments included change in VAS scores from baseline and proportion of patients achieving a 70% reduction in itch.1,2

Enstilar® can provide itch relief through the night for better sleep

36% of Enstilar® patients experienced a 70% reduction in sleep loss due to itch at 3 days (n=87/245) vs 23% of patients using foam vehicle (n=19/83; P=0.035).2,3

This increased to 71% (n=172/243) of Enstilar® patients at week 4 vs 40% of patients using foam vehicle (n=33/83; P<0.001)2,3

Proportion of patients achieving 70% relative
reduction in itch-related sleep loss2

Enstilar® (calcipotriol / betamethasone dipropionate) sleep loss data